87 related articles for article (PubMed ID: 2561638)
1. Selective inhibition of thrombin- and plasmin-induced platelet aggregation by a synthetic peptide disulfide.
Puri RN; Hu CJ; Bradford HN; Matsueda R; Umeyama H; Colman RW
Trans Assoc Am Physicians; 1989; 102():13-9. PubMed ID: 2561638
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation.
Matsueda R; Umeyama H; Puri RN; Bradford HN; Colman RW
Pept Res; 1994; 7(1):32-5. PubMed ID: 8019060
[TBL] [Abstract][Full Text] [Related]
3. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine.
Puri RN; Matsueda R; Umeyama H; Bradford HN; Colman RW
Eur J Biochem; 1993 May; 214(1):233-41. PubMed ID: 8389701
[TBL] [Abstract][Full Text] [Related]
4. Plasmin-induced platelet aggregation is accompanied by cleavage of aggregin and indirectly mediated by calpain.
Puri RN; Zhou FX; Colman RF; Colman RW
Am J Physiol; 1990 Dec; 259(6 Pt 1):C862-8. PubMed ID: 2148055
[TBL] [Abstract][Full Text] [Related]
5. Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Puri RN; Colman RW
Blood Coagul Fibrinolysis; 1993 Jun; 4(3):465-78. PubMed ID: 8329574
[TBL] [Abstract][Full Text] [Related]
6. Specificity of the sequence in Phe-Gln-Val-Val-Cys (-3-nitro-2-pyridinesulfenyl)-Gly-NH2--a selective inhibitor of thrombin-induced platelet aggregation.
Puri RN; Matsueda R; Umeyama H; Colman RW
Thromb Res; 1993 Nov; 72(3):183-91. PubMed ID: 8303657
[TBL] [Abstract][Full Text] [Related]
7. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide.
Puri RN; Hu CJ; Matsueda R; Umeyama H; Colman RW
Thromb Res; 1992 Mar; 65(4-5):533-47. PubMed ID: 1535463
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of thrombin-induced platelet aggregation by high molecular weight kininogen.
Puri RN; Gustafson EJ; Zhou FX; Bradford H; Colman RF; Colman RW
Trans Assoc Am Physicians; 1987; 100():232-40. PubMed ID: 3455067
[TBL] [Abstract][Full Text] [Related]
9. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
10. Characterization of plasmin-induced platelet aggregation.
Watabe A; Ohta M; Matsuyama N; Mizuno K; el Borai N; Tanimoto T; Kawanishi T; Hayakawa T
Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):341-52. PubMed ID: 9261893
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
12. High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Selim TE; Ghoneim HR; Uknis AB; Colman RW; DeLa Cadena RA
Eur J Biochem; 1997 Dec; 250(2):532-8. PubMed ID: 9428707
[TBL] [Abstract][Full Text] [Related]
13. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans.
Murphey LJ; Malave HA; Petro J; Biaggioni I; Byrne DW; Vaughan DE; Luther JM; Pretorius M; Brown NJ
J Pharmacol Exp Ther; 2006 Sep; 318(3):1287-92. PubMed ID: 16772538
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities.
Alexopoulos K; Fatseas P; Melissari E; Vlahakos D; Roumelioti P; Mavromoustakos T; Mihailescu S; Paredes-Carbajal MC; Mascher D; Matsoukas J
J Med Chem; 2004 Jun; 47(13):3338-52. PubMed ID: 15189031
[TBL] [Abstract][Full Text] [Related]
16. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen.
Kunapuli SP; Bradford HN; Jameson BA; DeLa Cadena RA; Rick L; Wassell RP; Colman RW
J Biol Chem; 1996 May; 271(19):11228-35. PubMed ID: 8626672
[TBL] [Abstract][Full Text] [Related]
17. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE
Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of staphylokinase on platelet aggregation.
Suehiro A; Oura Y; Ueda M; Kakishita E
Thromb Haemost; 1993 Nov; 70(5):834-7. PubMed ID: 7510426
[TBL] [Abstract][Full Text] [Related]
19. [A new thrombocyte aggregation-inhibiting and fibrinolysis-promoting synthetic molecule: RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide].
Udrardy M; Schwartzott D; Jackson K; McKee PA
Orv Hetil; 1995 Jan; 136(3):129-33. PubMed ID: 7870410
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
Burke FM; Warnock M; Schmaier AH; Mosberg HI
Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
